Argos Shares Good Results
Durham-based Argos Therapeutics is presenting two abstracts at the 2009 Annual Scientific Conference of the Canadian Society of Transplantation, outlining positive tests on its experimental therapy to prevent organ-transplant rejection.
Argos, a Duke University spinout started with help from a $10,000 North Carolina Biotechnology Center Business Development Loan in 1998, has developed several platform technologies and a diverse pipeline of product candidates based on the biology of dendritic cells -- the master switches that turn the immune system on and off. The company's focus is on developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection.
The Canadian presentations, by Argos' collaborating scientists from the University of Western Ontario, detail positive preclinical data for its soluble protein dubbed sCD83 in organ transplantation models.
Last year Argos closed on a $35.2 million financing package. In 2006 the National Institutes of Health awarded the firm $21 million to develop novel HIV immunotherapy candidates. Its personalized immunotherapy products are designed to train patients' immune systems to recognize, target and destroy unique features of their diseases.